BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 5, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

June 22, 2009

View Archived Issues

Data from first-in-human study of PF-00547659 in ulcerative colitis patients presented

Read More

Clinical data on mesalamine formulations in Crohn's disease, ulcerative colitis presented

Read More

Novel viral fusion inhibitors for the treatment of HIV disclosed

Read More

Novartis claims S1P1 receptor agonists for the treatment of autoimmune conditions

Read More

Novel GPR38 receptor agonists claimed by GlaxoSmithKline for gastrointestinal disorders

Read More

Antisense reports results from mouse studies of ATL-1101 in prostate cancer

Read More

Snapshots: promising clinical data on novel treatments for genitourinary cancer presented at ASCO

Read More

CK-2017357 begins first-in-man study

Read More

Grant supports Pharming's study of human lactoferrin for IBD

Read More

FDA approves Allergan's Ozurdex for macular edema following retinal vein occlusion

Read More

Akorn acquires TB drug Capastat Sulfate from Lilly

Read More

Adimab launches human antibody discovery platform and enters into two collaborations

Read More

Penwest and Otsuka sign third research and development agreement for TimerX technology

Read More

Advinus files IND with DCGI for a type 2 diabetes drug

Read More

Enrollment completed in phase IIb Albuferon trial in chronic hepatitis C

Read More

Dainippon Sumitomo obtains additional indication approval for AmBisome

Read More

Beneficial effects on glycemic control seen with albiglutide in clinical studies

Read More

Novel PDE4 inhibitors claimed by deCODE Genetics for the treatment of stroke

Read More

Phase I data disclosed on XOMA-052, a new anti-inflammatory approach for type 2 diabetes therapy

Read More

FDA grants pediatric exclusivity for The Medicines Company's Angiomax

Read More

Linagliptin shows clinical glycemic control in type 2 diabetes and aids wound healing in ob/ob mice

Read More

Patrys reports preclinical safety data for PAT-LM1 and PAT-SM6

Read More

BioLineRx announces results from preclinical studies of BL-1020 for schizophrenia

Read More

Results from pivotal clinical trial of lestaurtinib in AML reported by Cephalon

Read More

BL-5010 scheduled to begin phase I/II clinical trial in nonsurgical removal of skin lesions

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 4, 2025.
  • Illustration of chromosome unraveling down to the DNA

    First phase of synthetic human genome project successfully completes

    BioWorld
    The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • 3D Euro symbol

    Laigo raises €11.5M seed money for targeted protein degradation

    BioWorld Science
    Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing